Of the four studies, Huang et al. [51] was the only study that conducted a randomised controlled trial (RCT) where the recruited HER2+ breast cancer patients were assigned to either TA or TP chemotherapy by the investigator. This evidence concerns the gene ERBB2 and breast cancer.